Which tyrosinekinase inhibitor for which patient? – VEGFR, target therapy

Since the specific HER2 antibody trastuzumab is available, targeted therapy for breast cancer patients is becoming more and more the focus of new drug development. Additional tyrosine kinase inhibitors or antibodies are flooding the market for breast cancer treatment. Currently there are no indices...

Full description

Saved in:
Bibliographic Details
Main Authors: Schem, C, Kummerfeld, M, Bauerschlag, DO, Mundhenke, C, Sipos, B, Maass, N
Format: Conference Proceeding
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since the specific HER2 antibody trastuzumab is available, targeted therapy for breast cancer patients is becoming more and more the focus of new drug development. Additional tyrosine kinase inhibitors or antibodies are flooding the market for breast cancer treatment. Currently there are no indices available pointing out which patient will benefit best from these drugs. In this study we analyzed 156 paraffin embedded breast cancer and 55 matching lymphnode tissue samples for VEGFR 1/2, PDGFR α/β, FLT3 and cKIT expression. Corresponding clinical data was taken into account. All samples were evaluated by experienced breast cancer pathologists. Tyrosine kinase expression of VEGFR1/2 correlates with the nodal status (p
ISSN:0016-5751
1438-8804
DOI:10.1055/s-0028-1089303